drugset
drugset / Trial / NCT05708573

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

NCT05708573 ↗

Phase 1 Completed 20 enrolled Alexion Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the potential drug-drug interaction (DDI) between ALXN2040 and rosuvastatin.

Timeline

Start
2023-02-01
Primary completion
2023-03-23
Completion
2023-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Danicopan Small molecule — Oral
Subject Rosuvastatin Small molecule 20 mg Oral

Indications

No indication recorded.